Oncology

What Pharmacists Need to Know
About Targeted Therapies

This CME activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME activities may not contain the most up-to-date information available.

Click here to view our current activities in Oncology.

What Pharmacists Need to Know About Targeted Therapies

View Webcast - requires Flash & high-speed Internet (Tech. Requirements)
View/Download Slides
View/Download Syllabus

Unraveling the Molecular Basis of Cancer (16 Minutes)
An overview of major molecular pathways in cancer development that have been identified as potential targets for successful therapeutic interventions.
— Hai T. Tran, PharmD

How Do Targeted Therapies Work? (10 Minutes)
An exploration of the mechanism of action of recently FDA-approved and promising investigational targeted agents, with a discussion of target specificity for different solid tumors.
— Jon D. Herrington, PharmD, BCPS, BCOP

Clinical Update: Efficacy and Safety of Targeted Therapies
(16 Minutes)
A practical analysis of recent efficacy and safety results from clinical trials of FDA-approved and late-stage investigational targeted therapies in the treatment of patients with solid tumors.
— Cathy Eng, MD

Present and Future Role of Targeted Therapies in Cancer Care (17 Minutes)
A discussion of the evolving role of targeted therapies in the development and implementation of more effective strategies for the care of patients with solid tumors.
— Tarek Mekhail, MD, MSc, FRCSI, FRCSEd

CHAIR
Hai T. Tran, PharmD Assistant Professor Pharmacology – Research Cancer Medicine and Pharmacy The University of Texas M. D. Anderson Cancer Center Houston, Texas
FACULTY
Cathy Eng, MD Assistant Professor Department of Gastrointestinal Medical Oncology The University of Texas M.D. Anderson Cancer Center Houston, Texas
Jon D. Herrington, PharmD, BCPS, BCOP Hematology/Oncology Clinical Specialist Department of Pharmacy Scott & White Memorial Hospital Temple, Texas
Tarek Mekhail, MD, MSc, FRCSI, FRCSEd Director, Lung Cancer Medical Oncology Program Hematology/Medical Oncology The Cleveland Clinic Cleveland, Ohio

top

TARGET AUDIENCE

What Pharmacists Need to Know About Targeted Therapies will be directed to oncology pharmacists involved in the care of cancer patients.

ACTIVITY GOAL

The goal of What Pharmacists Need to Know About Targeted Therapies is to provide the latest data on the use of targeted therapies in the treatment of solid tumors.

LEARNING OBJECTIVES

Differentiate among major cellular signaling pathways involved in cancer development to identify potential targets for therapeutic interventions.
Assess how targeted therapies may work in the treatment of various solid tumors utilizing knowledge of the mechanism of action of these agents on cancer growth.
Analyze the efficacy and safety of targeted therapies in the treatment of solid tumors based on recent clinical trial results.
Evaluate treatment strategies for patients with solid tumors by integrating an understanding of the mechanisms, efficacy, and safety of current and emerging targeted therapies.

top

CE Information: Pharmacists

Projects In Knowledge is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This activity has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. The ACPE Universal Program Number assigned to the program, for 1 contact hour (0.1 CEU) is 052-000-06-021-H01.

Contract for Mutual Responsibility in CME/CE
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.

top

DISCLOSURE INFORMATION

The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.

For complete prescribing information on the products discussed during this CE activity, please see your current Physicians' Desk Reference (PDR).

Cathy Eng, MD, has disclosed that she will reference unlabeled/unapproved use of bevacizumab in clinical trials for breast cancer.

Jon D. Herrington, PharmD, BCPS, is on the speakers bureau of Amgen Inc; his wife is an employee of Pfizer Inc. Dr. Herrington has disclosed that he will not reference any unlabeled/unapproved uses of drugs or devices.

Tarek Mekhail, MD, MSc, FRCSI, FRCSEd, has received grant/research support from Celgene Corporation, Genentech, Inc, Merck & Co, Inc, and Vion Pharmaceuticals, Inc; is on the speakers bureau of Genentech, Inc, Eli Lilly and Company, and Sanofi-Aventis; and owns stock in Genentech, Inc and Pfizer Inc. Dr. Mekhail has disclosed that he will reference unlabeled/unapproved uses of bevacizumab.

Hai T. Tran, PharmD, has received grant/research support from AstraZeneca, Genetnech, Inc, Novartis Pharmaceuticals Corporation, and OSI Pharmaceuticals Inc; is a consultant for Genentech, Inc; and is on the speakers bureau of Genentech, Inc and Sanofi-Aventis. Dr. Tran has disclosed that he will not reference any unlabeled/unapproved uses of drugs or products in his presentation.

Peer Reviewer has disclosed no significant relationships.

Projects In Knowledge's staff members have no significant relationships to disclose.

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

This independent CE activity is supported by an educational grant from Genentech, Inc and OSI Oncology.

top

1775